Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
Results from adding adjuvant capecitabine to treatment for breast cancer patients

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.12.18
Views: 868

Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain

Dr Miguel Martin speaks to ecancer at SABCS 2018 about the randomised, phase II GEICAM/CIBOMA trial, looking at patients with early-stage triple-negative breast cancer being treated with the chemotherapy agent capecitabine following surgery and standard chemotherapy.

He says the results of the study indicated that treating these patients with capecitabine did not significantly improve their outcomes, however elaborates on potential reasons for the lack of statistical significance.

Dr Martin also elaborates on some unexpected results from the trial, and what the next steps may be to better understand the results of the trial.

Watch his press conference here.

Read more about this work here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation